Clinical trial
Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization in Age Related Macular Degeneration
NCT00527475 is registered in ClinicalTrials.gov with Texas Retina Associates as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization in Age Related Macular Degeneration
- Lead sponsor
- Texas Retina Associates
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2007
- Completion date
- January 31, 2010
- Enrollment
- 60 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.